Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9MXL

Complex of the phosphorylated human cystic fibrosis transmembrane conductance regulator (CFTR) with (R)-BPO-27 and ATP/Mg

This is a non-PDB format compatible entry.
Summary for 9MXL
Entry DOI10.2210/pdb9mxl/pdb
EMDB information48717
DescriptorCystic fibrosis transmembrane conductance regulator, (6R,12R)-6-(5-bromofuran-2-yl)-7,9-dimethyl-8,10-dioxo-11-phenyl-7,8,9,10-tetrahydro-6H-pyrimido[4',5':3,4]pyrrolo[2,1-c][1,4]benzoxazine-2-carboxylic acid, MAGNESIUM ION, ... (6 entities in total)
Functional Keywordsinhibitor, cftr, membrane protein
Biological sourceHomo sapiens (human)
Total number of polymer chains1
Total formula weight169981.24
Authors
Young, P.G.,Fiedorczuk, K.,Chen, J. (deposition date: 2025-01-20, release date: 2025-08-06, Last modification date: 2026-02-18)
Primary citationYoung, P.G.,Fiedorczuk, K.,Chen, J.
Structure of CFTR bound to (R)-BPO-27 unveils a pore-blockage mechanism.
Nat Commun, 16:7059-7059, 2025
Cited by
PubMed Abstract: Hyperactivation of the cystic fibrosis transmembrane conductance regulator (CFTR) contributes to secretory diarrhea, a major cause of pediatric mortality worldwide, and autosomal dominant polycystic kidney disease (ADPKD), the most common inherited cause of end-stage renal disease. Selective CFTR inhibition is a potential therapeutic strategy, with (R)-BPO-27 emerging as a promising candidate. Here, we present a cryo-EM structure of CFTR bound to (R)-BPO-27 at an overall resolution of 2.1 Å. Contrary to the previous hypothesis that it inhibits CFTR current by competition with ATP, we demonstrate that (R)-BPO-27 instead directly occludes the chloride-conducting pore while permitting ATP hydrolysis, thus uncoupling the two activities. Furthermore, we find that inhibitor binding requires some degree of NBD separation, as the inhibition rate inversely correlates with the probability NBD dimerization. These findings clarify the compound's mechanism and provide a molecular basis for optimizing its clinical potential.
PubMed: 40750590
DOI: 10.1038/s41467-025-62199-7
PDB entries with the same primary citation
Experimental method
ELECTRON MICROSCOPY (2.1 Å)
Structure validation

249697

PDB entries from 2026-02-25

PDB statisticsPDBj update infoContact PDBjnumon